Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.515 USD | +7.65% | +10.28% | +24.00% |
05-14 | Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating | MT |
05-14 | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.00% | 492M | |
+26.00% | 49.18B | |
+0.44% | 42.11B | |
+50.18% | 40.37B | |
-5.26% | 28.85B | |
+12.46% | 26.09B | |
-21.68% | 18.71B | |
+8.40% | 13.26B | |
+31.14% | 12.32B | |
-0.36% | 11.99B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Fulcrum Therapeutics Completes Patient Enrollment for Phase 3 Study of Losmapimod